PEAK6 Group’s GW Pharmaceuticals Plc American Depositary Shares GWPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
$8.44M Buy
60,500
+5,000
+9% +$710K 0.04% 525
2018
Q1
$6.25M Sell
55,500
-9,600
-15% -$1.21M 0.03% 690
2017
Q4
$8.59M Buy
65,100
+46,000
+241% +$5.4M 0.04% 545
2017
Q3
$1.94M Buy
19,100
+700
+4% +$75K 0.01% 1414
2017
Q2
$1.84M Buy
+18,400
New +$1.98M 0.01% 1413
2016
Q4
Sell
-1,000
Closed -$133K 5249
2016
Q3
$133K Buy
+1,000
New +$95.6K ﹤0.01% 3421
2015
Q3
Sell
-30,200
Closed -$3.71M 5777
2015
Q2
$3.71M Buy
30,200
+19,700
+188% +$2.23M 0.02% 1028
2015
Q1
$957K Buy
+10,500
New +$853K 0.01% 1922
2014
Q3
Sell
-500
Closed -$54K 5357
2014
Q2
$54K Buy
+500
New +$34.8K ﹤0.01% 4030

Other funds holding GWPH

PEAK6 Group's GWPH Position: Q2 2018 in Review

PEAK6 Group reduced its GW Pharmaceuticals Plc American Depositary Shares (GWPH) stake by 43% in Q2 2018, selling an estimated $485K and leaving 4,476 shares worth $625K. The position accounts for ﹤0.01% of the portfolio, ranked #2382.

PEAK6 Group first reported a position in GWPH in Q2 2015 and has held it in 5 quarters since. The position peaked at $889K in Q1 2018. 254 funds tracked by Wall St. Rank hold GWPH as of Q2 2018.

  • PEAK6 Group held 4,476 shares of GW Pharmaceuticals Plc American Depositary Shares worth $625K as of Q2 2018.
  • PEAK6 Group sold 3,416 GW Pharmaceuticals Plc American Depositary Shares shares in Q2 2018, an estimated $485K.
  • GW Pharmaceuticals Plc American Depositary Shares made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #2382 holding.
  • PEAK6 Group first reported a position in GW Pharmaceuticals Plc American Depositary Shares in Q2 2015 and has held it in 5 quarters since.
  • PEAK6 Group's GW Pharmaceuticals Plc American Depositary Shares position peaked at $889K in Q1 2018.
  • 254 funds tracked by Wall St. Rank held GW Pharmaceuticals Plc American Depositary Shares as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.